CytoReason to License Its IBD Disease Model to Sanofi in Expanded Multiyear, Multimillion Dollar Deal TEL AVIV, Israel, Jan. 23, 2023 (GLOBE NEWSWIRE) -- CytoReason, a leader and pioneer in computational disease modeling, today announced an expansion of its collaboration with Sanofi. The multiyear...

CytoReason Announces Expanded Collaboration Deal with Pfizer to Deliver AI for Drug Discovery and Development TEL AVIV, Israel, Sept. 20, 2022 (GLOBE NEWSWIRE) -- CytoReason today announced an extension of its multi-year partnership with Pfizer to use CytoReason’s artificial intelligence technology for...